282.6K XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Amy Elazzouzi | Senior Vice President, Finance | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 1,404 | 82,278 | - | 7.8 | 10,881 | Common Stock |
| Janet Jill Hopkins | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 2,534 | 269,794 | - | 7.8 | 19,639 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 20,221 | 482,440 | - | 7.8 | 156,796 | Common Stock |
| Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 2,151 | 209,456 | - | 7.7 | 16,670 | Common Stock |
| Amy Elazzouzi | Senior Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 29,760 | 29,760 | - | - | Stock Option (Right to Buy) | |
| Amy Elazzouzi | Senior Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 45,240 | 83,682 | - | 0 | Common Stock | |
| Janet Jill Hopkins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 79,365 | 79,365 | - | - | Stock Option (Right to Buy) | |
| Janet Jill Hopkins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 120,635 | 272,328 | - | 0 | Common Stock | |
| Elisabet de los Pinos | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 255,680 | 255,680 | - | - | Stock Option (Right to Buy) | |
| Elisabet de los Pinos | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 194,320 | 502,661 | - | 0 | Common Stock | |
| Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 90,475 | 211,607 | - | 0 | Common Stock | |
| Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 59,525 | 59,525 | - | - | Stock Option (Right to Buy) | |
| Conor Kilroy | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 59,525 | 59,525 | - | - | Stock Option (Right to Buy) | |
| Conor Kilroy | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 90,475 | 186,475 | - | 0 | Common Stock | |
| Elisabet de los Pinos | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 21 Jan 2025 | 15,955 | 304,692 | - | 7.7 | 122,381 | Common Stock |
| Amy Elazzouzi | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 21 Jan 2025 | 1,001 | 38,442 | - | 7.7 | 7,679 | Common Stock |
| Janet Jill Hopkins | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.36 per share. | 18 Nov 2024 | 11,822 | 151,693 | - | 9.4 | 110,663 | Common Stock |
| Amy Elazzouzi | Vice President, Finance | Sale of securities on an exchange or to another person at price $ 10.74 per share. | 29 Oct 2024 | 553 | 39,443 | - | 10.7 | 5,938 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 10.74 per share. | 29 Oct 2024 | 9,200 | 320,647 | - | 10.7 | 98,788 | Common Stock |
| Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.25 per share. | 18 Oct 2024 | 2,631 | 154,407 | - | 4.3 | 11,182 | Common Stock |
| Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.48 per share. | 18 Oct 2024 | 5,000 | 159,407 | - | 5.5 | 27,400 | Common Stock |
| Julie B. Feder | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 18 Oct 2024 | 25,131 | 134,276 | - | 12.0 | 302,361 | Common Stock |
| Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 17,500 | 68,257 | - | - | Stock Option (Right to Buy) | |
| Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 2,631 | 32,359 | - | - | Stock Option (Right to Buy) | |
| Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 5,000 | 120,547 | - | - | Stock Option (Right to Buy) | |
| Julie B. Feder | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.74 per share. | 18 Oct 2024 | 17,500 | 151,776 | - | 2.7 | 47,950 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.74 per share. | 18 Oct 2024 | 24,992 | 354,839 | - | 2.7 | 68,478 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 18 Oct 2024 | 24,992 | 329,847 | - | 12.0 | 300,839 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 24,992 | 336,171 | - | - | Stock Option (Right to Buy) | |
| Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 9.85 per share. | 16 Oct 2024 | 7,383 | 121,132 | - | 9.9 | 72,723 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 5,474 | 0 | - | - | Stock Option (Right to Buy) | |
| Elisabet de los Pinos | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.76 per share. | 27 Sep 2024 | 5,474 | 329,847 | - | 5.8 | 31,530 | Common Stock |
| Antony C. Mattessich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 10,500 | 10,500 | - | 0 | Common Stock | |
| Antony C. Mattessich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 10,500 | 10,500 | - | 0 | Common Stock | |
| Conor Kilroy | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 96,000 | 96,000 | - | 0 | Common Stock | |
| Conor Kilroy | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 144,000 | 144,000 | - | - | Stock Option (Right to Buy) | |
| Hopkins Janet Jill | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 41,485 | 41,485 | - | - | Stock Option (Right to Buy) | |
| Feder Julie B. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 103,715 | 103,715 | - | - | Stock Option (Right to Buy) | |
| de los Pinos Elisabet | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 237,065 | 237,065 | - | - | Stock Option (Right to Buy) | |
| Feder B. Julie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 71,285 | 134,276 | - | 0 | Common Stock | |
| de los Pinos Elisabet | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 162,935 | 324,373 | - | 0 | Common Stock | |
| Hopkins Janet Jill | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 28,515 | 163,515 | - | 0 | Common Stock | |
| de los Pinos Elisabet | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 23 Jan 2024 | 15,853 | 161,438 | - | 7.6 | 121,141 | Common Stock |
| B. Julie Feder | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 23 Jan 2024 | 6,609 | 62,991 | - | 7.6 | 50,521 | Common Stock |
| Cadmus Rich | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| Mark De Rosch | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 42,250 | 58,635 | - | 0 | Common Stock | |
| Mark De Rosch | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Julie B. Feder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Julie B. Feder | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 48,750 | 72,985 | - | 0 | Common Stock | |
| Elisabet de los Pinos | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 187,500 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Elisabet de los Pinos | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 121,875 | 190,526 | - | 0 | Common Stock | |
| Cadmus Rich | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 34,125 | 58,703 | - | 0 | Common Stock | |
| Cadmus Rich | See Remarks | Sale of securities on an exchange or to another person at price $ 12.45 per share. | 31 Oct 2022 | 1,672 | 24,578 | - | 12.4 | 20,813 | Common Stock |
| Elisabet de los Pinos | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.46 per share. | 31 Oct 2022 | 5,706 | 68,651 | - | 12.5 | 71,082 | Common Stock |
| Julie B. Feder | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.45 per share. | 31 Oct 2022 | 2,015 | 24,235 | - | 12.5 | 25,090 | Common Stock |
| Mark De Rosch | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 12.46 per share. | 31 Oct 2022 | 1,115 | 16,385 | - | 12.5 | 13,890 | Common Stock |
| Antony C. Mattessich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Elisabet de los Pinos | Director, See Remarks | 02 Nov 2021 | 1,510 | 0 | - | - | Series A-2 Preferred Stock | ||
| Elisabet de los Pinos | Director, See Remarks | 02 Nov 2021 | 4,552 | 131,412 | - | 0 | Common Stock | ||
| Elisabet de los Pinos | Director, See Remarks | 02 Nov 2021 | 3,042 | 0 | - | - | Series A-1 Preferred Stock |